An Exclusive Continuing Education Publication of Acadiana Consultant Pharmacy Service
Author, Publisher, Editor-in Chief, Typesetter & Printer, Charles S. Feucht,PD,FASCP PharmD candidate
Updated Black Box Warnings for Erythropoiesis-Stimulating Agents
The FDA has recently approved revised labeling for Aranesp, Epogen, and Procrit, erythropoiesis-stimulating agents (ESA) used to treat certain types of anemia.
The updated black box warnings discuss tumor growth and shortened survival in cancer patients and an increased risk of serious cardiovascular events and mortality in chronic renal failure patients when Hgb >12 g/dL are achieved with ESA therapy.